drugset / Trial / NCT06375811
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
Phase 3
Active not recruiting
97 enrolled
Yale University
Duke University · collabJohns Hopkins University · collabNorthwestern University · collabUniversity of Colorado, Denver · collabUniversity of North Carolina · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Timeline
- Start
- 2024-03-16
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Elagolix | Small molecule | 200 mg | Oral |